Geriatricians are urging caution on a wave of new psychiatric drugs for older patients

A growing lineup of newly approved psychiatric medications is meeting a wall of caution from the doctors who care for the oldest patients, who warn that the drugs often arrive with thin evidence about how they behave in aging bodies and, in some cases, with serious safety flags. The concern, aired at a major geriatrics meeting, is not that the medications are useless but that they are being prescribed to a population they were rarely tested on.

Older adults are among the heaviest users of psychiatric drugs, prescribed for depression, insomnia, agitation and the behavioral symptoms of dementia. Yet the clinical trials that win these drugs approval tend to enroll younger, healthier participants, leaving the physicians who treat frail seniors to make decisions with limited guidance about risks that matter most in that group.

What the geriatricians told the AGS meeting

The warnings came from experts reviewing recent approvals at a national geriatrics conference. As reported from the American Geriatrics Society’s 2026 annual meeting, specialists said an expanding pipeline of novel antipsychotics and insomnia treatments carries persistently thin evidence and significant safety concerns for older adults, fostering caution among geriatricians. Their core objection was structural: most of the newest agents were studied primarily in younger people with schizophrenia, leaving clinicians with little data on how they perform in elderly patients who are frail, cognitively impaired, or already taking many other drugs.

One geriatrician quoted from the meeting, Dan Haimowitz, urged colleagues to avoid antipsychotics whenever possible in older patients — a stance that reflects how the potential harms weigh against often modest benefits in that population. The broader message from the panel was a call for more research focused specifically on older adults, so that prescribing is guided by evidence rather than extrapolation from studies done in a very different group.

Boxed warnings and the dementia mortality signal

Part of what drives the caution is a well-documented danger with a class of these drugs. Certain antipsychotics carry a boxed warning — the strongest alert the Food and Drug Administration attaches to a label — for an increased risk of death in older adults with dementia-related psychosis. That warning is not new to the field, and its real-world consequences have been studied closely; one analysis in JAMA Network Open examined how the antipsychotic boxed warning affected medication use and health outcomes in elderly patients with dementia, underscoring how significant regulators consider the mortality signal to be.

The tension for clinicians is that the very symptoms these drugs are sometimes reached for — agitation, aggression or psychosis in dementia — are also where the mortality risk is most established. That leaves geriatricians weighing a difficult trade-off: a distressing behavioral symptom on one side, and a drug carrying a warning about increased death on the other. The experts’ guidance leans toward nonpharmacological approaches first and drugs only when clearly necessary, at the lowest effective dose and for the shortest time.

Why older bodies change the risk calculation

The pharmacology of aging compounds the evidence gap. Older adults process drugs more slowly, are more sensitive to sedation and blood-pressure effects, and are far more likely to be taking multiple medications that can interact. A psychiatric drug that is well tolerated in a 30-year-old trial participant can produce disproportionate drowsiness, confusion or unsteadiness in an 80-year-old, and those effects feed directly into the falls and cognitive decline that geriatric care works to prevent.

Frailty and polypharmacy — the common reality of carrying a long list of prescriptions — further constrain safe prescribing. Every added drug raises the odds of an interaction, and sedating or anticholinergic psychiatric medications can worsen the very confusion or instability a clinician is trying to avoid. The specialists’ point is that these factors are precisely what the pivotal trials often screen out, so the published safety data may understate the risks that show up in real geriatric practice.

What cautious prescribing looks like in practice

The guidance does not amount to a blanket refusal to treat mental illness in older adults, which would leave real suffering unaddressed. Rather, it frames newer psychiatric drugs as options to be used deliberately: starting low, monitoring closely, revisiting whether the drug is still needed, and preferring approaches with a longer track record when one exists. For insomnia and agitation in particular, experts emphasize behavioral and environmental strategies before reaching for a pill.

The call for more geriatric-specific research is the throughline. Until trials routinely include the frail, older, medically complex patients who end up taking these drugs, clinicians will keep prescribing partly in the dark, relying on judgment to bridge a gap the evidence has not closed. The geriatricians’ caution is essentially a request to narrow that gap before the newest medications become routine in the population most exposed to their risks.

For patients and families, the practical implication is to treat a new psychiatric prescription in an older adult as a decision worth discussing in detail — asking what it was tested on, what warnings it carries, and whether the potential benefit justifies the uncertainty that the specialists have flagged.

This article was researched and written with the assistance of AI and reviewed by an editor prior to publication.

More from Morning Overview